<DOC>
	<DOCNO>NCT02942563</DOCNO>
	<brief_summary>The concurrent neoadjuvant chemoradiation therapy standard care local advance rectal cancer ( LARC ) , however , regimen may induce sort adverse event , part even severer . A number pilot study show high rate complete resection neoadjuvant chemotherapy alone , result increase ratio pathological complete response ( pCR ) , associate overall survival ( OS ) . Here , investigator adopt three active cytotoxic agent ( Fluorouracil , Oxaliplatin , Irinotecan , FOLFOXIRI ) neoadjuvant chemotherapy regimen replace concurrent chemoradiation improve ratio pCR .</brief_summary>
	<brief_title>Total Neoadjuvant Therapy Locally Advanced Rectal Cancer</brief_title>
	<detailed_description>This multicenter , phase II trial ass efficacy/safety triplet regimen ( FOLFOXIRI ) patient LARC . After 4 cycle FOLFOXIRI 2 week later , patient evaluate senior radiologist , oncologist surgeon pelvic MRI , CT Positron Emission Computed Tomography ( PET-CT ) . The patient go surgery ( TME ) tumor response good enough complete resection decision MDT , otherwise , patient receive pelvic radiotherapy ( 45Grey/25Fraction 5.4Grey/3Fraction boost tumor bed ) combine capecitabine ( 625mg/M^2 , bid po , d1-5 , qw ) , additional four cycle modify FOLFOX6 ( mFOLFOX6 ) chemotherapy TME . All patient receive 4-8 cycle mFOLFOX6 adjuvant chemotherapy TME .</detailed_description>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<criteria>Age ≥ 18 75 year diagnosis Diagnosis rectal adenocarcinoma ECOG status : 0～1 Clinical stage II ( T34 , N0 ) stage III ( T14 , N12 ) Adequate bone marrow , hepatic renal function assess follow laboratory requirement conduct within 7 day start study treatment : Leukocytes ≥ 3.0 x109/ L , Absolute neutrophil count ( ANC ) ≥ 1.5 x109/ L Platelet count ≥ 100 x109/ L , Hemoglobin ( Hb ) ≥ 9g/ dL . Total bilirubin ≤1.5 x upper limit normal ( ULN ) . Alanine aminotransferase ( ALT ) Aspartate aminotransferase ( AST ) ≤ 3 x ULN . Serum creatinine ≤ 1.5 x ULN . Signed informed consent ; Patient receive pelvic radiotherapy Patient receive systemic chemotherapy Pregnant Nursing woman Had metastatic disease Uncontrolled comorbid illness concurrent disease Patient second malignant disease within 5 year Patients refuse sign informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>